Healthcare · Medical - Devices
Price
$23.61
Market Cap
$1.1B
Employees
1,600
Beta
1.26
Avg Volume
737,268
CEO
James Patrick Mackin
Business Description
Artivion Inc. is a global company that develops, produces, and supplies medical devices and implantable human tissues. Its product range includes BioGlue, a polymer derived from bovine blood protein combined with a cross-linking agent, utilized in cardiac, vascular, neurological, and pulmonary surgical applications. The company also offers heart preservation services and the PhotoFix bovine pericardial patch, in addition to E-vita Open Plus and E-vita Open Neo devices. For the treatment of aortic vascular conditions, Artivion provides specialized stent graft systems. These include E-xtra design engineering systems for aortic vascular diseases, E-nside as an off-the-shelf solution for thoraco-abdominal disease, E-vita THORACIC 3G for endovascular repair of thoracic aortic aneurysms, E-nya for minimally invasive repair of descending aorta lesions, and the E-tegra system for abdominal aortic aneurysms. Furthermore, its offerings address peripheral and renal artery treatments with the E-ventus BX balloon-expandable stent graft and the E-liac system for aneurysmal iliac arteries and their side branches. The company's diverse portfolio extends to synthetic vascular grafts for use in open aortic and peripheral vascular surgeries, PerClot (an absorbable powdered hemostat for surgical procedures), and cardiac laser therapy products for angina management. Preservation services include CryoVein for femoral veins and CryoArtery for femoral arteries. Artivion also manufactures On-X prosthetic aortic and mitral heart valves, along with the On-X ascending aortic prosthesis. Supplementary devices feature CarbonAid CO2 diffusion catheters and Chord-X ePTFE sutures designed for mitral chordal replacement, as well as ascyrus medical dissection stents. Beyond products, the company offers pyrolytic carbon coating services to other medical device manufacturers. Artivion Inc. serves a broad client base, including physicians, hospitals, other healthcare facilities, and specialists such as cardiac, vascular, thoracic, and general surgeons. Established in 1984 and headquartered in Kennesaw, Georgia, the company adopted the name Artivion Inc. in January 2022, having previously operated as CryoLife, Inc.
Business History
Price History (1 Year)
Revenue & Net Income Trend
The directional story — useful even when net income is negative.
Revenue
The top line — total sales before any costs or taxes are subtracted. A measure of how much business the company is doing.
Net Income
The bottom line — profit left after subtracting all expenses, interest, and taxes from revenue. Reflects accounting profitability, but includes non-cash items like depreciation, so it isn't the same as cash earned.
Operating Cash Flow
The real cash generated by the day-to-day business — selling products, paying suppliers, collecting from customers. Calculated from net income by adding back non-cash items and adjusting for timing (unpaid bills, unsold inventory). When OCF consistently lags net income, the reported profit may not be converting to real money.
| Period | Revenue | Net Income | Net Margin | YoY/QoQ |
|---|
Key Metrics
API Direct from provider
CALC Derived from statements
P/E Ratio (Price per dollar of earnings)
APIStock Price / EPS (Diluted)
97.09
Stock Price: $23.61
EPS (Diluted): 0.22
EPS (Diluted): 0.22
P/B Ratio (Price vs net asset value)
APIStock Price / Book Value Per Share
4.61
Stock Price: $23.61
Total Equity: $448.23M
Shares: 47,162,000
Total Equity: $448.23M
Shares: 47,162,000
EV/EBITDA (Total value vs operating profit)
APIEnterprise Value / EBITDA
20.73
Market Cap: $1.15B
Total Debt: $254.92M
Cash: $64.91M
EBITDA: $63.82M
Total Debt: $254.92M
Cash: $64.91M
EBITDA: $63.82M
Enterprise Value (Takeover price (cap + debt - cash))
APIMarket Cap + Total Debt - Cash
$2.3B
Market Cap: $1.15B
Total Debt: $254.92M
Cash: $64.91M
Total Debt: $254.92M
Cash: $64.91M
Gross Margin (Revenue left after direct costs)
APIGross Profit / Revenue
61.3%
Gross Profit: $270.45M
Revenue: $441.33M
Revenue: $441.33M
Operating Margin (Revenue left after all operations)
APIOperating Income / Revenue
6.1%
Operating Income: $26.75M
Revenue: $441.33M
Revenue: $441.33M
Net Margin (Revenue left as actual profit)
APINet Income / Revenue
2.2%
Net Income: $9.77M
Revenue: $441.33M
Revenue: $441.33M
ROE (Profit from shareholder equity)
APINet Income / Total Equity
2.7%
Net Income: $9.77M
Total Equity: $448.23M
Total Equity: $448.23M
ROIC (Profit from all invested capital)
APINOPAT / Invested Capital
3.0%
Operating Income: $26.75M
Tax Rate: 33.9%
Equity: $448.23M
Total Debt: $254.92M
Cash: $64.91M
Tax Rate: 33.9%
Equity: $448.23M
Total Debt: $254.92M
Cash: $64.91M
Current Ratio (Can it pay short-term bills)
APICurrent Assets / Current Liabilities
2.99
Current Assets: $303.55M
Current Liabilities: $101.56M
Current Liabilities: $101.56M
Debt/Equity (Leverage — debt vs equity)
CALCTotal Debt / Total Equity
0.57
Short-Term Debt: $5.38M
Long-Term Debt: $249.54M
Total Debt: $254.92M
Total Equity: $448.23M
Long-Term Debt: $249.54M
Total Debt: $254.92M
Total Equity: $448.23M
Rev/Share (Top-line per share)
CALCRevenue / Shares Outstanding
$9.36
Revenue: $441.33M
Shares: 47,162,000
Shares: 47,162,000
Book Value/Share (Net assets per share)
CALC(Total Assets - Total Liabilities) / Shares
$9.50
Total Equity: $448.23M
Shares: 47,162,000
Shares: 47,162,000
FCF/Share (Real cash generated per share)
CALC(Operating Cash Flow + CapEx) / Shares
$-0.02
Operating CF: $38.13M
CapEx: -$39.04M
Shares: 47,162,000
CapEx: -$39.04M
Shares: 47,162,000
CapEx is negative (outflow) — added to OCF to get FCF
Div Yield (Annual income from holding)
APILast Annual Dividend / Stock Price
0.0%
Last Dividend: N/A
Stock Price: $23.61
Stock Price: $23.61
Payout Ratio (Earnings paid out as dividends)
Dividends Paid / Net Income
—
Dividends Paid: N/A
Net Income: $9.77M
Net Income: $9.77M
Dividends paid not available in cash flow statement
Industry Benchmarks
Compares AORT against LLM-researched typical ranges for its
industry. One research call per industry, cached indefinitely — every stock in the same industry
reuses the same baseline.
Deep Analysis
Pre-flight intelligence scans the company first, then routes to the right analytical methods.
0
Company Classification
— What type of company is this?
1
Industry Landscape
— Where is the industry headed?
2
Company Momentum
— Where is this company trending?
3
Forward Projection
— 1Y & 2Y projected metrics (requires Layer 1 + 2)
4a
DCF Valuation
— Present value of future cash flows
4b
Earnings Power Value
— Floor value — worth with zero growth
4c
Anchored PE
— Industry PE adjusted for growth differential
4d
Reverse DCF
— What growth is the market pricing in?
4e
Revenue-Based DCF
— For growth/narrative companies (skip if mature earner)
4f
Anchored P/S
— Price-to-Sales peer comparison (skip if mature earner)
4g
Scenario Analysis
— Bull / Base / Bear (skip if mature earner)
4h
Dividend Discount Model
— For dividend/income stocks only
4i
Book Value Analysis
— For deep value / turnaround stocks only
4j
Insider Activity
— Are insiders buying or selling?
4f
Cash Flow Quality
— How trustworthy is the FCF?
4g
Debt Maturity Risk
— Can it handle its debt?
4h
Macro Environment
— Rates, market valuation, volatility
4i
Sector Intelligence
— How does this company compare within its sector?
4j
Revenue Confidence
— How reliable is the growth projection?
4k
Sensitivity Analysis
— How fragile is the fair value estimate?
4l
Sector Demand Cycle
— Is the sector in a boom, steady state, or contraction?
5
AI Investigation
— Adaptive research engine (Claude)
5b
Thesis Evaluation
— What does the market believe? (narrative/platform stocks only)
6
Valuation Synthesis
— Weighted verdict from all methods (requires Layer 4)
Income Statement (Annual)
Last updated: Jun 27, 2026 9:06am (1h ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $298.8M | $313.8M | $354.0M | $388.5M | $441.3M |
| Cost of Revenue | $101.3M | $111.3M | $124.8M | $139.8M | $170.9M |
| Gross Profit | $197.5M | $202.5M | $229.2M | $248.8M | $270.5M |
| Operating Expenses | $189.4M | $196.3M | $223.4M | $209.9M | $243.7M |
| Operating Income | $8.1M | $6.2M | $5.7M | $38.9M | $26.7M |
| Net Income | -$14.8M | -$19.2M | -$30.7M | -$13.4M | $9.8M |
| EBITDA | $26.0M | $25.7M | $26.8M | $51.0M | $63.8M |
| EPS | $-0.38 | $-0.48 | $-0.75 | $-0.32 | $0.22 |
| EPS (Diluted) | — | — | — | — | — |
Balance Sheet (Annual)
Last updated: Jun 27, 2026 9:06am (1h ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | $55.0M | $39.4M | $58.9M | $53.5M | $64.9M |
| Total Current Assets | $247.7M | $247.3M | $280.7M | $290.1M | $303.6M |
| Total Assets | $793.1M | $762.8M | $792.4M | $789.1M | $884.8M |
| Current Liabilities | $45.0M | $49.7M | $57.9M | $66.8M | $101.6M |
| Long-Term Debt | $307.5M | $306.5M | $305.5M | $314.2M | $249.5M |
| Total Liabilities | $492.3M | $478.5M | $510.6M | $512.9M | $436.6M |
| Total Equity | $300.7M | $284.3M | $281.8M | $276.2M | $448.2M |
| Retained Earnings | $2.0M | -$17.2M | -$47.9M | -$61.3M | -$51.5M |
Cash Flow (Annual)
Last updated: Jun 27, 2026 9:06am (1h ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | -$2.6M | -$5.2M | $18.8M | $22.2M | $38.1M |
| Capital Expenditure | -$13.1M | -$10.7M | -$7.4M | -$11.2M | -$39.0M |
| Free Cash Flow | -$15.7M | -$15.9M | $11.4M | $11.0M | $-911,000 |
| Acquisitions (net) | $0 | $0 | $0 | $0 | $0 |
| Debt Repayment | — | — | — | — | — |
| Dividends Paid | — | — | — | — | — |
| Stock Buybacks | -$1.9M | -$1.8M | $-559,000 | $0 | $0 |
| Net Change in Cash | -$6.9M | -$15.7M | $19.6M | -$5.5M | $11.4M |
Analyst Estimates (Annual)
Last updated: Jun 27, 2026 9:06am (1h ago)| Metric | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|
| Revenue |
$540.0M $533.1M – $546.8M
|
$601.2M $601.2M – $601.2M
|
$677.9M $668.0M – $688.2M
|
$763.9M $752.7M – $775.5M
|
| EBITDA |
$56.2M $55.5M – $56.9M
|
$62.6M $62.6M – $62.6M
|
$70.6M $69.5M – $71.6M
|
$79.5M $78.4M – $80.7M
|
| Net Income |
$19.3M $18.9M – $19.7M
|
$39.3M $33.1M – $45.7M
|
$56.1M $55.1M – $57.2M
|
$74.0M $72.6M – $75.5M
|
| EPS | — | — | — | — |
Growth Trends (YoY %)
Last updated: Jun 27, 2026 9:06am (1h ago)| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue Growth | +5.0% | +12.8% | +9.8% | +13.6% |
| Gross Profit Growth | +2.5% | +13.2% | +8.6% | +8.7% |
| Operating Income Growth | -23.6% | -7.4% | +577.0% | -31.2% |
| Net Income Growth | -29.4% | -59.9% | +56.5% | +173.1% |
| EBITDA Growth | -1.4% | +4.3% | +90.3% | +25.2% |
Insider Trading (Recent)
Last updated: Jun 27, 2026 9:06am (1h ago)
Type codes
PPurchase
SSale
AAward / grant
MOption exercise
FIn-kind (tax)
CConversion
GGift
DReturn to issuer
All SEC Form 4 codes
Open market
- P Purchase
- Open-market or private purchase of shares.
- S Sale
- Open-market or private sale of shares.
Compensation (Rule 16b-3)
- A Award / grant
- Grant or award of securities (RSUs, options, etc.) under Rule 16b-3.
- D Return to issuer
- Securities disposed back to the company under Rule 16b-3.
- F In-kind (tax)
- Shares withheld or delivered to pay the option-exercise price or tax — not an open-market sale.
- I Discretionary
- Discretionary transaction under an employee plan — Rule 16b-3(f).
- M Option exercise
- Exercise or conversion of a derivative (option/RSU) into shares — exempt.
Derivatives
- C Conversion
- Conversion of a derivative security into the underlying shares.
- E Short expiration
- Expiration of a short derivative position.
- H Long expiration
- Expiration or cancellation of a long derivative position with value received.
- O OTM exercise
- Exercise of an out-of-the-money derivative.
- X ITM exercise
- Exercise of an in-the-money or at-the-money derivative.
Other exempt
- G Gift
- Bona fide gift of securities.
- L Small acquisition
- Small acquisition under Rule 16a-6.
- W Inheritance
- Acquisition or disposition by will or the laws of descent.
- Z Voting trust
- Deposit into or withdrawal from a voting trust.
Other
- J Other
- Other acquisition or disposition (explained in a Form 4 footnote).
- K Equity swap
- Transaction in an equity swap or similar instrument.
- U Tender / buyout
- Disposition via tender of shares in a change-of-control transaction.
Compensation-plan codes (A, D, F, M) are routine and rarely directional. Open-market P (buy) and S (sale) carry the most signal.
| Date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| 2026-06-11 | GREEN ANDREW M | M-Exempt | 30,000.00 | $11.03 | $330,900 |
| 2026-06-11 | GREEN ANDREW M | M-Exempt | 14,001.00 | $18.44 | $258,178 |
| 2026-06-11 | GREEN ANDREW M | S-Sale | 30,000.00 | $20.69 | $620,820 |
| 2026-06-11 | GREEN ANDREW M | S-Sale | 14,001.00 | $20.71 | $289,919 |
| 2026-06-11 | GREEN ANDREW M | M-Exempt | 14,001.00 | $18.44 | $258,178 |
| 2026-06-11 | GREEN ANDREW M | M-Exempt | 30,000.00 | $11.03 | $330,900 |
| 2026-06-01 | GREEN ANDREW M | 0.00 | $0.00 | $0 | |
| 2026-06-01 | GREEN ANDREW M | 30,000.00 | $11.03 | $330,900 | |
| 2026-06-01 | GREEN ANDREW M | 14,001.00 | $18.44 | $258,178 | |
| 2026-06-02 | SEMEDO ANTHONY B. | J-Other | 6,325.00 | $0.00 | $0 |
| 2026-06-02 | SEMEDO ANTHONY B. | J-Other | 6,325.00 | $0.00 | $0 |
| 2026-05-18 | Borgstrom Marna P | A-Award | 7,576.00 | $0.00 | $0 |
| 2026-05-18 | SEMEDO ANTHONY B. | A-Award | 7,576.00 | $0.00 | $0 |
| 2026-05-18 | Salveson Jon W | A-Award | 7,576.00 | $0.00 | $0 |
| 2026-05-18 | Hoff Elizabeth A | A-Award | 7,576.00 | $0.00 | $0 |
| 2026-05-18 | Burbank Jeffrey H | A-Award | 7,576.00 | $0.00 | $0 |
| 2026-05-18 | Bullock James | A-Award | 7,576.00 | $0.00 | $0 |
| 2026-05-18 | BEVEVINO DANIEL J | A-Award | 7,576.00 | $0.00 | $0 |
| 2026-05-18 | ACKERMAN THOMAS F | A-Award | 7,576.00 | $0.00 | $0 |
| 2026-05-14 | Borgstrom Marna P | A-Award | 7,850.00 | $0.00 | $0 |
Dividend History (Last 20)
Last updated: Jun 27, 2026 9:06am (1h ago)| Date | Dividend | Declaration | Record | Payment |
|---|---|---|---|---|
| 2015-12-09 | $0.03 | 2015-10-22 | 2015-12-11 | 2015-12-18 |
| 2015-09-09 | $0.03 | 2015-07-22 | 2015-09-11 | 2015-09-18 |
| 2015-06-10 | $0.03 | 2015-05-21 | 2015-06-12 | 2015-06-19 |
| 2015-03-11 | $0.03 | 2015-02-13 | 2015-03-13 | 2015-03-20 |
| 2014-12-10 | $0.03 | 2014-10-23 | 2014-12-12 | 2014-12-19 |
| 2014-09-10 | $0.03 | 2014-07-30 | 2014-09-12 | 2014-09-19 |
| 2014-06-11 | $0.03 | 2014-05-22 | 2014-06-13 | 2014-06-20 |
| 2014-03-12 | $0.03 | 2014-02-19 | 2014-03-14 | 2014-03-21 |
| 2013-12-11 | $0.03 | 2013-11-21 | 2013-12-13 | 2013-12-20 |
| 2013-09-11 | $0.03 | 2013-08-21 | 2013-09-13 | 2013-09-20 |
| 2013-06-12 | $0.03 | 2013-05-28 | 2013-06-14 | 2013-06-21 |
| 2013-03-12 | $0.03 | 2013-02-13 | 2013-03-14 | 2013-03-21 |
| 2012-12-12 | $0.03 | 2012-11-19 | 2012-12-14 | 2012-12-21 |
| 2012-09-12 | $0.03 | 2012-08-21 | 2012-09-14 | 2012-09-21 |
Narrative Economics
The story the market is telling about this stock — the intangible X-factor
(founder mythology, cult dynamics, TAM-of-imagination) that moves price beyond
what cash flows alone explain. After Shiller, Narrative Economics.
No narrative profile yet for AORT — it's generated by the pipeline (
market-narrative step).
No community reviews yet for AORT.
Be the first — hit How to Contribute, have any AI review this page, and paste its take back here.
My Notes
personal — only you see this
Sign in to save personal notes and rate your interest in this stock.
Data via Financial Modeling Prep · Cached for performance · fmp
v1.1.352 · d1100787 · 2026-06-26 11:39:30